The Challenge
Susan's oncologist at a leading academic center was about to prescribe Rybrevant based on her biomarker reports.
Our Impact
Cancer Commons identified a critical distinction—her tumor had ERBB2 alterations, not EGFR mutations that Rybrevant targets. We clarified that Enhertu was the evidence-supported therapy for her biomarker profile.
The Outcome
Near-complete resolution of liver and bone metastases within weeks. She avoided wasting time on an ineffective therapy that, at the time, would have cost thousands of dollars per month.
